# BIBW 2992 (Afatinib) in Head & Neck Cancer

> **NCT00514943** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 124 (actual)

## Conditions studied

- Head and Neck Neoplasms
- Carcinoma, Squamous Cell

## Interventions

- **DRUG:** BIBW 2992
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00514943
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-03
- **Final completion:** 2013-07
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2016-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00514943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00514943, "BIBW 2992 (Afatinib) in Head & Neck Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00514943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*